GRIFOLS SA -
Grifols is one of the first companies to receive funding from the European Investment Bank (EIB) through the new European Fund for Strategic Investments (EFSI), also known as the Juncker Plan
-
The loan will be used to support investment in R&D, focusing primarily on the search for new indications for plasma proteins, including the treatment of Alzheimer's disease, amongst others
-
The financial conditions include a fixed interest rate for a tenor of ten yearswith a grace period of two years
Barcelona, October 28, 2015: Grifols (MCE: GRF, MCE: GRF.P and NASDAQ:GRFS), one of the world's largest plasma product manufacturers and a pioneer in the research and development of therapeutic alternatives designed to contribute to both scientific and social development, has agreed a loan for 100 million euros with the European Investment Bank (EIB) following conclusion of financial and legal negotiations, including due diligence.
Grifols will use the EIB loan to support its investment in R&D, focusing primarily on the search for new indications for plasma proteins, including the treatment of Alzheimer's disease, vascular diseases, cardiovascular surgery and arterial thrombosis, amongst others.
Grifols is one of the first European companies to receive a loan from the new European Fund for Strategic Investments (EFSI), also known as the Juncker Plan. This is an initiative supported by the EIB and the European Commission, with the aim of reactivating investment in strategic projects throughout Europe, and its objectives include strengthening R&D in European companies.
Grifols hopes that its successful engagement with the EIB will encourage other Spanish companies to consider this source of funding for their projects.
Key conditions of the loan: - Principal (amount borrowed): 100 million euros
- Interest rate: fixed:
- Tenor: 10 years
- Grace period: 2 years
- Date of signature of contract: October 28, 2015
The European Investment Bank (EIB) is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals.
Grifols is a global company that has been committed to serving people's health since 1940. In 2015 the company celebrates 75 years of improving people's health and well- being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use.
The company is present in more than 100 countries worldwide and its headquarters are located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donation centers in the U.S., and is a leading producer of plasma-derived biological medicines. Within the field of in vitro diagnostics it is a world leader in transfusion medicine, and has a very strong position in immunology and hemostasis, enabling it to offer integrated solutions to clinical analysis laboratories, blood banks and transfusion centers.
Its sales in 2014 exceeded 3,350 million euros, and it employs approximately 14,000 members of staff. Grifols allocates a share of its income to R&D, an investment that demonstrates the company's commitment to scientific progress.
The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF).Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ:GRFS). For more information visit: www.grifols.com
The facts and figures contained in this report that do not refer to historical data are 'future projections and assumptions'. Words and expressions such as 'believe', 'hope', 'anticipate', 'predict', 'expect', 'intend', 'should', 'will seek to achieve', 'it is estimated', 'future' and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential
impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Act 24/1988, of 28 July, on Stock Exchanges; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation.
|
distributed by
|
